PL1768999T3 - Przeciwciało sHIgM12 użyteczne w leczeniu stwardnienia rozsianego - Google Patents

Przeciwciało sHIgM12 użyteczne w leczeniu stwardnienia rozsianego

Info

Publication number: PL1768999T3
Authority: PL; Poland
Prior art keywords: multiple sclerosis; treat multiple; antibody useful; shigm12 antibody; shigm12
Prior art date: 2004-06-30

Application number

PL05789212T

Other languages

English (en)

Inventor

Larry R Pease

Suresh Radhakrishnan

Keulen Virginia Van

Bogoljub Ciric

Koji Iijima

Hirohito Kita

Original Assignee

Mayo Found Medical Education & Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-30

Filing date

2005-06-30

Publication date

2013-12-31

2004-06-30 Priority claimed from US10/881,661 external-priority patent/US7501119B2/en

2004-11-05 Priority claimed from US10/983,104 external-priority patent/US20060099203A1/en

2005-06-30 Application filed by Mayo Found Medical Education & Res filed Critical Mayo Found Medical Education & Res

2013-12-31 Publication of PL1768999T3 publication Critical patent/PL1768999T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

PL05789212T 2004-06-30 2005-06-30 Przeciwciało sHIgM12 użyteczne w leczeniu stwardnienia rozsianego PL1768999T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10/881,661 US7501119B2 (en)	2004-06-30	2004-06-30	Methods and molecules for modulating an immune response
US10/983,104 US20060099203A1 (en)	2004-11-05	2004-11-05	B7-DC binding antibody
EP05789212.7A EP1768999B1 (en)	2004-06-30	2005-06-30	sHIgM12 antibody useful to treat multiple sclerosis
PCT/US2005/023440 WO2006004988A2 (en)	2004-06-30	2005-06-30	B7-dc binding antibody

Publications (1)

Publication Number	Publication Date
PL1768999T3 true PL1768999T3 (pl)	2013-12-31

Family

ID=35783376

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL05789212T PL1768999T3 (pl)	2004-06-30	2005-06-30	Przeciwciało sHIgM12 użyteczne w leczeniu stwardnienia rozsianego

Country Status (6)

Country	Link
EP (2)	EP2481750A1 (pl)
JP (5)	JP5902367B2 (pl)
CA (1)	CA2572098C (pl)
ES (1)	ES2427147T3 (pl)
PL (1)	PL1768999T3 (pl)
WO (1)	WO2006004988A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7052694B2 (en) *	2002-07-16	2006-05-30	Mayo Foundation For Medical Education And Research	Dendritic cell potentiation
WO2006004988A2 (en) *	2004-06-30	2006-01-12	Mayo Foundation For Medical Education And Research	B7-dc binding antibody
RU2017132160A (ru)	2008-12-09	2019-02-08	Дженентек, Инк.	Антитела к pd-l1 и их применение для усиления функции t-клеток
WO2011150161A2 (en)	2010-05-27	2011-12-01	Dow Global Technologies Llc	Methods for producing crosslinkable silyl group-containing polyoxyalkylene polymers.
BR112013009673B1 (pt) *	2010-10-19	2022-05-17	Mayo Foundation For Medical Education And Research	Anticorpos igm humanos isolados, método de preparação dos mesmos, kits, composição farmacêutica e ácido nucleico isolado
IN2014MN02274A (pl) *	2012-04-17	2015-08-07	Mayo Foundation
WO2013161958A1 (ja) *	2012-04-27	2013-10-31	日本ケミカルリサーチ株式会社	新規な発現ベクター
WO2015048312A1 (en)	2013-09-26	2015-04-02	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
KR20240110004A (ko)	2014-03-14	2024-07-12	노파르티스 아게	Lag-3에 대한 항체 분자 및 그의 용도
EP3191127A1 (en)	2014-09-13	2017-07-19	Novartis AG	Combination therapies of egfr inhibitors
KR102513870B1 (ko)	2014-10-14	2023-03-23	노파르티스 아게	Pd-l1에 대한 항체 분자 및 그의 용도
US11180543B2 (en)	2014-11-07	2021-11-23	Mayo Foundation For Medical Education And Research	Treatment of neonatal hypoxia including impairments or effects thereof
CN107530429B (zh)	2015-03-30	2021-12-07	斯特库比股份有限公司	特异性针对糖基化的pd-l1的抗体及其使用方法
US11933786B2 (en)	2015-03-30	2024-03-19	Stcube, Inc.	Antibodies specific to glycosylated PD-L1 and methods of use thereof
EP3383412A4 (en)	2015-12-02	2019-06-05	Stcube, Inc.	SPECIFIC ANTIBODIES TO GLYCOSED PD-1 AND METHOD OF USE THEREOF
KR20180130541A (ko)	2016-03-29	2018-12-07	주식회사 에스티큐브앤컴퍼니	글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
ES2973870T3 (es)	2016-03-29	2024-06-24	Univ Texas	Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
US11746152B2 (en)	2016-07-20	2023-09-05	Stcube, Inc.	Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
EP3694545A4 (en)	2017-10-11	2021-12-01	Board Of Regents, The University Of Texas System	HUMAN PD-L1 ANTIBODIES AND PROCEDURES FOR USE
CN111757894B (zh) *	2018-02-14	2025-02-25	Abba疗法股份公司	抗人类pd-l2抗体
US11976128B2 (en)	2018-03-23	2024-05-07	Board Of Regents, The University Of Texas System	Human PD-L2 antibodies and methods of use therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
ES2171392T3 (es) *	1990-08-29	2002-09-16	Ct Hospitalier Regional De Nan	Poliligandos de proteina unidos a un nucleo de proteina estable.
JPH09100300A (ja) *	1995-10-03	1997-04-15	Hagiwara Yoshihide	抗癌ヒトモノクローナル抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列
EP1297847A3 (en) *	1996-01-23	2003-05-07	Genentech, Inc.	Anti-CD18 antibodies in stroke
JPH11127855A (ja) *	1997-10-27	1999-05-18	Japan Energy Corp	組換え型抗ヒトＴＮＦ−αヒトモノクローナル抗体
CA2315944A1 (en) *	1997-12-24	1999-07-08	Diatech Pty. Ltd.	Bifunctional molecules
AU757961B2 (en) *	1998-09-30	2003-03-13	Sankyo Company Limited	Anti-Fas antibodies
MXPA02008144A (es) *	2000-02-23	2002-11-29	Amgen Inc	Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
JP2001342148A (ja) *	2000-03-29	2001-12-11	Sankyo Co Ltd	ヒト化抗Ｆａｓ抗体を含有する医薬
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
US20020168367A1 (en) *	2000-04-28	2002-11-14	Planet Biotechnology Incorporated	Novel immunoadhesins for treating and preventing viral and bacterial diseases
US20030059427A1 (en) *	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
CA2414331C (en) *	2000-06-28	2011-11-29	Genetics Institute, Llc.	Pd-l2 molecules: novel pd-1 ligands and uses therefor
AR039067A1 (es) *	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US7052694B2 (en) *	2002-07-16	2006-05-30	Mayo Foundation For Medical Education And Research	Dendritic cell potentiation
CA2508375C (en) *	2002-12-02	2014-05-27	Abgenix, Inc.	Antibodies directed to tumor necrosis factor and uses thereof
GB0402720D0 (en) *	2004-02-07	2004-03-10	Bentley Motors Ltd	A rest
WO2006004988A2 (en) *	2004-06-30	2006-01-12	Mayo Foundation For Medical Education And Research	B7-dc binding antibody

2005
- 2005-06-30 WO PCT/US2005/023440 patent/WO2006004988A2/en not_active Ceased
- 2005-06-30 CA CA2572098A patent/CA2572098C/en not_active Expired - Lifetime
- 2005-06-30 JP JP2007520393A patent/JP5902367B2/ja not_active Expired - Fee Related
- 2005-06-30 EP EP12164916A patent/EP2481750A1/en not_active Withdrawn
- 2005-06-30 PL PL05789212T patent/PL1768999T3/pl unknown
- 2005-06-30 ES ES05789212T patent/ES2427147T3/es not_active Expired - Lifetime
- 2005-06-30 EP EP05789212.7A patent/EP1768999B1/en not_active Expired - Lifetime
2011
- 2011-11-11 JP JP2011247243A patent/JP2012080887A/ja not_active Withdrawn
2016
- 2016-01-05 JP JP2016000360A patent/JP2016128429A/ja not_active Withdrawn
2017
- 2017-10-11 JP JP2017197691A patent/JP6625106B2/ja not_active Expired - Fee Related
2019
- 2019-10-08 JP JP2019185180A patent/JP2020015759A/ja active Pending

Also Published As

Publication number	Publication date
JP6625106B2 (ja)	2019-12-25
JP2016128429A (ja)	2016-07-14
EP1768999A2 (en)	2007-04-04
WO2006004988A3 (en)	2006-04-06
JP2012080887A (ja)	2012-04-26
EP1768999A4 (en)	2008-09-17
JP2018016640A (ja)	2018-02-01
JP2008505639A (ja)	2008-02-28
ES2427147T3 (es)	2013-10-29
EP2481750A1 (en)	2012-08-01
EP1768999B1 (en)	2013-06-19
CA2572098C (en)	2015-01-27
CA2572098A1 (en)	2006-01-12
WO2006004988A2 (en)	2006-01-12
JP2020015759A (ja)	2020-01-30
JP5902367B2 (ja)	2016-04-13

Publication	Publication Date	Title
PL1768999T3 (pl)	2013-12-31	Przeciwciało sHIgM12 użyteczne w leczeniu stwardnienia rozsianego
TWI366570B (en)	2012-06-21	Antibodies to madcam
IL191600A (en)	2015-11-30	A specific neutralizing antibody against il-6 from a person and various aspects related to it
IL180852A0 (en)	2007-07-04	Anti-cd154 antibodies
IL181575A0 (en)	2007-07-04	Anti-ox40l antibodies
IL228032A0 (en)	2013-09-30	Antibodies
IL237756A0 (en)	2015-05-31	Antibody compositions
SI1850873T1 (sl)	2019-05-31	Protitelesa proti TGFBETA
IL191340A (en)	2015-08-31	Monoclonal antibodies against e8o
GB0420466D0 (en)	2004-10-20	Anti-glucan antibodies
AU2003218456A8 (en)	2003-10-20	Antibodies that specifically bind to gmad
EP1827491A4 (en)	2010-07-14	TREATMENT OF MULTIPLE SCLEROSIS
ZA200701952B (en)	2008-10-29	Anti-OX40L antibodies
IL172276A0 (en)	2006-04-10	Cross-reference to related application
EP1780221A4 (en)	2007-10-03	ANTI-SYNOVIOLIN ANTIBODY
GB0418415D0 (en)	2004-09-22	Antibody
GB0402076D0 (en)	2004-03-03	Travel ease
ZA200804254B (en)	2009-01-28	Human monoclonal antibodies to O8E
GB0420771D0 (en)	2004-10-20	Antibody
GB0402970D0 (en)	2004-03-17	Engines
GB0411936D0 (en)	2004-06-30	2 to 1
GB0402642D0 (en)	2004-03-10	Antibodies
GB0402641D0 (en)	2004-03-10	Antibodies
GB0413163D0 (en)	2004-07-14	Improvements to signware
GB0413479D0 (en)	2004-07-21	Novel antibodies